NEPH · Nephros, Inc.

Revenue increased 6.9% to $5.2 million in Q1 2026 from $4.9 million in the prior year, reflecting Nephros' established position in programmatic sales through recurring filter replacements in healthcare and dialysis settings. These sustained procurement cycles provide a stable base for the medical-grade water filtration specialist, even as non-recurring emergency response deployments eased from elevated Q1 2025 levels tied to waterborne outbreaks. The growth highlights the company's focus on predictable revenue streams amid shifting demand patterns.

Gross profit fell 5.1% to $3.0 million, contracting the gross margin to 57.4%, as product costs and revenue mix dynamics weighed on profitability. While topline expansion continued, the margin profile underscores challenges in maintaining blends when scaling across customer segments. Operating income dropped sharply 82.9% to $97 thousand from $566 thousand, producing a slim 1.9% operating margin, as expense leverage did not keep pace with revenue gains. Net income declined 74.9% to $140 thousand, with diluted EPS at $0.01 compared to $0.05, signaling profitability pressures despite revenue momentum.

Strategically, a new value-added reseller (VAR) dedicated to high-volume commercial food and beverage markets differentiates Nephros from partners offering mixed medical-commercial products, targeting quick-service restaurants and hospitality for equipment protection and PFAS filtration benefits. Management's operating plans aim to control costs and drive revenue growth to generate cash flows funding ongoing filtration development, marketing, sales, and working capital needs. However, liquidity remains sensitive to demand fluctuations from economic or competitive conditions, where failure to meet plans could hinder cost cuts and strain resources. Investors should track execution on commercial expansion and working capital management to assess sustainability of the revenue base.